Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.39 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5654879 | 0.95 | HDAC1 (0.49) | HDAC1PTGER4SIRT5HDAC4HDAC6 | |
| SCHEMBL5655189 | 0.93 | HDAC1 (0.46) | HDAC1PTGER4SIRT5MCHR1HTRA1 | |
| SCHEMBL5651596 | 0.92 | HDAC1 (0.47) | HDAC1PTGER4SIRT5HDAC4HDAC6 | |
| SCHEMBL5653535 | 0.92 | HDAC1 (0.45) | HDAC1PTGER4SIRT5MCHR1HDAC4 | |
| SCHEMBL5654763 | 0.91 | HDAC1 (0.47) | HDAC1PTGER4SIRT5MCHR1HDAC4 | |
| SCHEMBL5653786 | 0.90 | HDAC1 (0.47) | HDAC1PTGER4MCHR1 | |
| SCHEMBL5653474 | 0.90 | HDAC1 (0.46) | HDAC1PTGER4SIRT5HDAC4HDAC6 | |
| SCHEMBL5653273 | 0.90 | HDAC1 (0.44) | HDAC1PTGER4SIRT5MCHR1HTRA1 | |
| SCHEMBL5652787 | 0.89 | HDAC1 (0.46) | HDAC1PTGER4MCHR1 | |
| SCHEMBL5653864 | 0.89 | HDAC1 (0.45) | HDAC1PTGER4SIRT5MCHR1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142638-A1 | Ornithine derivatives as prostaglandin e2 agonists or antagonists | ASTELLAS PHARMA INC. (JP) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142638-A1 | Ornithine derivatives as prostaglandin e2 agonists or antagonists | PTGER4, OXER1, RXFP4 | HDAC1 1416/4885PTGER4 1/4885SIRT5 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.